Tesaro (TSRO) Hit on Negative Article
Tweet
Share
E-mailGet Alerts TSRO Hot Sheet
Join SI Premium – FREE
Tesaro (NASDAQ: TSRO) sees intra-day weakness following an negative article at SeekingAlpha.
According to the post from Apsara Biotech, "... we think the inexorable climb in TSRO is likely to be short-lived. Tesaro's primary drug candidate is an uninspiring chemotherapy-induced nausea and vomiting ("CINV") drug that has completed no new trials since being discarded for a tiny fraction of its current valuation several years ago."
Shares are down 2.6 percent mid-day.
Link
According to the post from Apsara Biotech, "... we think the inexorable climb in TSRO is likely to be short-lived. Tesaro's primary drug candidate is an uninspiring chemotherapy-induced nausea and vomiting ("CINV") drug that has completed no new trials since being discarded for a tiny fraction of its current valuation several years ago."
Shares are down 2.6 percent mid-day.
Link
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Buyout firm Vista explores $3B sale of private markets data provider Allvue - Reuters
- New York Fed raises Q3 2026 GDP forecast to 2.3%
Create E-mail Alert Related Categories
Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
